|
Market Closed -
Nasdaq
20:00:00 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 73.39 USD | +2.16% |
|
+1.44% | +12.39% |
| 10-05 | Monopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC Filing | MT |
| 09-21 | Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to S&P Biotechnology Select Industry Index | CI |
Company Valuation: Monopar Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 40.42 | 30.62 | 5.058 | 134.2 | 436.4 | 492.6 | - | - |
| Change | - | -24.23% | -83.48% | 2,552.79% | 225.25% | 12.89% | - | - |
| Enterprise Value (EV) 1 | 40.42 | 30.62 | 5.058 | 134.2 | 296 | 373.8 | 348 | 324.5 |
| Change | - | -24.23% | -83.48% | 2,552.79% | 120.6% | 26.31% | -6.9% | -6.78% |
| P/E | -4.4x | -2.86x | -0.56x | -5.35x | -35.3x | -29.6x | -29.3x | -24.5x |
| PBR | - | - | - | - | 3.17x | 4.65x | 5.5x | 5.22x |
| PEG | - | -0.2x | 0x | -0.2x | 0.6x | -0.9x | -29.07x | -1.3x |
| Capitalization / Revenue | - | - | - | - | - | - | 17.4x | 5.81x |
| EV / Revenue | - | - | - | - | - | - | 12.3x | 3.83x |
| EV / EBITDA | - | - | - | - | -17.7x | -9.17x | -14x | -120x |
| EV / EBIT | -4.43x | -2.91x | -0.57x | -8.3x | -17.7x | -13.7x | -8.33x | -11.4x |
| EV / FCF | - | - | - | -20.9x | -24.3x | -14.9x | -17.2x | -42.5x |
| FCF Yield | - | - | - | -4.77% | -4.12% | -6.71% | -5.81% | -2.35% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.65 | -4.15 | -3.05 | -4.11 | -1.85 | -2.48 | -2.505 | -2.996 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 28.26 | 84.73 |
| EBITDA 1 | - | - | - | - | -16.7 | -40.77 | -24.81 | -2.694 |
| EBIT 1 | -9.127 | -10.54 | -8.831 | -16.16 | -16.7 | -27.29 | -41.79 | -28.39 |
| Net income 1 | -9.103 | -10.52 | -8.402 | -15.6 | -13.72 | -21.46 | -26.62 | -29.6 |
| Net Debt 1 | - | - | - | - | -140.4 | -118.8 | -144.6 | -168.1 |
| Reference price 2 | 16.05 | 11.85 | 1.70 | 22.00 | 65.30 | 73.39 | 73.39 | 73.39 |
| Nbr of stocks (in thousands) | 2,518 | 2,584 | 2,973 | 6,098 | 6,683 | 6,712 | - | - |
| Announcement Date | 24/03/22 | 23/03/23 | 28/03/24 | 31/03/25 | 27/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -28.97x | - | -8.91x | - | 482M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 21.29x | 26.33x | 13.12x | 0.34% | 38.09B | |
| Weighted average by Cap. | 26.48x | 25.23x | 15.65x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MNPR Stock
- Valuation Monopar Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
